Vaccine Escape: Exploring the simplest model

Duration: 24 mins 46 secs

Share this media item:

Embed this media item:

<iframe width="_width_" height="_height_" src="https://sms.cam.ac.uk/media/3436478/embed" frameborder="0" scrolling="no" allowfullscreen></iframe>

Choose size:

About this item

Available Formats

About this item

Description:	Gog, J 23rd February 2021 - 10:30-10:50 "Please also see https://www.medrxiv.org/content/10.1101/2021.03.14.21253544v2" medRxivmedRxiv Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple model As a counter measure to the SARS-CoV-2 pandemic there has been swift development and clinical trial assessment of candidate vaccines, with subsequent deployment as part of mass vaccination campaigns. However, the SARS-CoV-2 virus has demonstrated the ability to mutate and develop variants, which can modify epidemiological properties and potentially also the effectiveness of vaccines. The widespread deployment of highly effective vaccines may rapidly exert selection pressure on the SARS-CoV-2 virus directed towards mutations that escape the vaccine induced immune response. This is particularly concerning whilst infection is widespread. By developing and analysing a mathematical model of two population groupings with differing vulnerability and contact rates, we explore the impact of the deployment of vaccine amongst the population on R, cases, disease abundance and vaccine escape pressure. The results from this model illustrate two insights (i) vaccination aimed at reducing prevalence could be more effective at reducing disease than directly vaccinating the vulnerable; (ii) the highest risk for vaccine escape can occur at intermediate levels of vaccination. This work demonstrates a key principle that the careful targeting of vaccines towards particular population groups could reduce disease as much as possible whilst limiting the risk of vaccine escape. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by UKRI through the JUNIPER modelling consortium [grant number MR/V038613/1]. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Not applicable All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Not applicable

Description:

Gog, J
23rd February 2021 - 10:30-10:50

"Please also see https://www.medrxiv.org/content/10.1101/2021.03.14.21253544v2"
medRxivmedRxiv
Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple model
As a counter measure to the SARS-CoV-2 pandemic there has been swift development and clinical trial assessment of candidate vaccines, with subsequent deployment as part of mass vaccination campaigns. However, the SARS-CoV-2 virus has demonstrated the ability to mutate and develop variants, which can modify epidemiological properties and potentially also the effectiveness of vaccines. The widespread deployment of highly effective vaccines may rapidly exert selection pressure on the SARS-CoV-2 virus directed towards mutations that escape the vaccine induced immune response. This is particularly concerning whilst infection is widespread. By developing and analysing a mathematical model of two population groupings with differing vulnerability and contact rates, we explore the impact of the deployment of vaccine amongst the population on R, cases, disease abundance and vaccine escape pressure. The results from this model illustrate two insights (i) vaccination aimed at reducing prevalence could be more effective at reducing disease than directly vaccinating the vulnerable; (ii) the highest risk for vaccine escape can occur at intermediate levels of vaccination. This work demonstrates a key principle that the careful targeting of vaccines towards particular population groups could reduce disease as much as possible whilst limiting the risk of vaccine escape. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by UKRI through the JUNIPER modelling consortium [grant number MR/V038613/1]. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Not applicable All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Not applicable


Created:	2021-02-24 11:39
Collection:	JUNIPER Research Meeting
Publisher:	Isaac Newton Institute
Copyright:	Gog, J
Language:	eng (English)

Available Formats

Format	Quality	Bitrate	Size
MPEG-4 Video	640x360	1.14 Mbits/sec	212.95 MB	View	Download
WebM	640x360	406.85 kbits/sec	73.85 MB	View	Download
iPod Video	480x270	489.53 kbits/sec	88.80 MB	View	Download
MP3	44100 Hz	249.73 kbits/sec	45.36 MB	Listen	Download
Auto *	(Allows browser to choose a format it supports)